A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
Principal Investigator
Jagbir GillOverview
Body Locations and Systems
Kidney TransplantationDiagnosis and Therapy
Kidney TransplantationClinicalTrials.gov#
NCT02610296Status
RecruitingStudy Start/End
Aug 22, 2016 to Dec 31, 2019Locations
St. Paul's Hospital, Vancouver General Hospital
Name/Title
Angela Ogniben, Research Coordinator Phone
604-875-4111 ext.64707Email Address
aogniben@providencehealth.bc.caPurpose of Study
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.